Liu, Y.; Vorobyeva, A.; Orlova, A.; Konijnenberg, M.W.; Xu, T.; Bragina, O.; Loftenius, A.; Rosander, E.; Frejd, F.Y.; Tolmachev, V.
Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics 2022, 14, 1092.
https://doi.org/10.3390/pharmaceutics14051092
AMA Style
Liu Y, Vorobyeva A, Orlova A, Konijnenberg MW, Xu T, Bragina O, Loftenius A, Rosander E, Frejd FY, Tolmachev V.
Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics. 2022; 14(5):1092.
https://doi.org/10.3390/pharmaceutics14051092
Chicago/Turabian Style
Liu, Yongsheng, Anzhelika Vorobyeva, Anna Orlova, Mark W. Konijnenberg, Tianqi Xu, Olga Bragina, Annika Loftenius, Erica Rosander, Fredrik Y. Frejd, and Vladimir Tolmachev.
2022. "Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071" Pharmaceutics 14, no. 5: 1092.
https://doi.org/10.3390/pharmaceutics14051092
APA Style
Liu, Y., Vorobyeva, A., Orlova, A., Konijnenberg, M. W., Xu, T., Bragina, O., Loftenius, A., Rosander, E., Frejd, F. Y., & Tolmachev, V.
(2022). Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071. Pharmaceutics, 14(5), 1092.
https://doi.org/10.3390/pharmaceutics14051092
